Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome
Long QT syndrome (LQTS) is one of several primary electrical disorders or hereditary arrhythmia syndromes along with the short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Since its initial recognition in 1957 by Jervell and Lange-Nielsen ( Am Heart J. 19...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2007-04, Vol.153 (4), p.53-58 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 58 |
|---|---|
| container_issue | 4 |
| container_start_page | 53 |
| container_title | The American heart journal |
| container_volume | 153 |
| creator | Daubert, James P., MD Zareba, Wojciech, MD, PhD Rosero, Spencer Z., MD Budzikowski, Adam, MD, PhD Robinson, Jennifer L., MS Moss, Arthur J., MD |
| description | Long QT syndrome (LQTS) is one of several primary electrical disorders or hereditary arrhythmia syndromes along with the short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Since its initial recognition in 1957 by Jervell and Lange-Nielsen ( Am Heart J. 1957;54:59-68), LQTS has been intimately associated with risk for sudden cardiac death. The implantable defibrillator was developed by Morowski et al ( N Engl J Med. 1980;303:322-4) as a treatment to prevent sudden cardiac death. Consequently, implanted cardioverter-defibrillator therapy deserves serious consideration as an important therapy for LQTS. |
| doi_str_mv | 10.1016/j.ahj.2007.01.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70325970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002870307000841</els_id><sourcerecordid>70325970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-5db931bc6ebd6a860cb1cf0bd9cbcf037a8079e71911152445b81b23668ddb143</originalsourceid><addsrcrecordid>eNp9kV-L1DAUxYMo7uzoB_BFAoJvrTdtmrYIgiy6CguiruBbyJ9bJ7VtapJZmW9vhhlY2AdfcnPhnMO9v0vICwYlAybejKXajWUF0JbASqiaR2TDoG8L0XL-mGwAoCq6FuoLchnjmFtRdeIpuWBt3fMe6g35-c1PSP1A3bxOaklK59aoYJ2_w5AwUIuD08FNk0o-0LTDoNYDdQtdVXK4pEj_urSjk19-0a-3NB4WG_yMz8iTQU0Rn5_rlvz4-OH26lNx8-X689X7m8LUvE9FY3VfM20EaitUJ8BoZgbQtjc617pVHbQ9tqxnjDUV543umK5qITprNeP1lrw-5a7B_9ljTHJ20WAed0G_jzJvXzV9frfk1QPh6PdhybNJ1gAXHDqosoqdVCb4GAMOcg1uVuEgGcgjdDnKDF0eoUtgMkPPnpfn5L2e0d47zpSz4O1JgBnEncMgo8noDFoX0CRpvftv_LsHbjO5xRk1_cYDxvstZKwkyO_Hqx-PDm3-dZzV_wAxQ6bC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504640802</pqid></control><display><type>article</type><title>Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Daubert, James P., MD ; Zareba, Wojciech, MD, PhD ; Rosero, Spencer Z., MD ; Budzikowski, Adam, MD, PhD ; Robinson, Jennifer L., MS ; Moss, Arthur J., MD</creator><creatorcontrib>Daubert, James P., MD ; Zareba, Wojciech, MD, PhD ; Rosero, Spencer Z., MD ; Budzikowski, Adam, MD, PhD ; Robinson, Jennifer L., MS ; Moss, Arthur J., MD</creatorcontrib><description>Long QT syndrome (LQTS) is one of several primary electrical disorders or hereditary arrhythmia syndromes along with the short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Since its initial recognition in 1957 by Jervell and Lange-Nielsen ( Am Heart J. 1957;54:59-68), LQTS has been intimately associated with risk for sudden cardiac death. The implantable defibrillator was developed by Morowski et al ( N Engl J Med. 1980;303:322-4) as a treatment to prevent sudden cardiac death. Consequently, implanted cardioverter-defibrillator therapy deserves serious consideration as an important therapy for LQTS.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2007.01.025</identifier><identifier>PMID: 17394903</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Cardiac arrhythmia ; Cardiovascular ; Defibrillators, Implantable - adverse effects ; Heart attacks ; Humans ; Long QT Syndrome - drug therapy ; Long QT Syndrome - therapy ; Mortality ; Mutation</subject><ispartof>The American heart journal, 2007-04, Vol.153 (4), p.53-58</ispartof><rights>2007</rights><rights>Copyright Elsevier Limited Apr 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c349t-5db931bc6ebd6a860cb1cf0bd9cbcf037a8079e71911152445b81b23668ddb143</citedby><cites>FETCH-LOGICAL-c349t-5db931bc6ebd6a860cb1cf0bd9cbcf037a8079e71911152445b81b23668ddb143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002870307000841$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17394903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daubert, James P., MD</creatorcontrib><creatorcontrib>Zareba, Wojciech, MD, PhD</creatorcontrib><creatorcontrib>Rosero, Spencer Z., MD</creatorcontrib><creatorcontrib>Budzikowski, Adam, MD, PhD</creatorcontrib><creatorcontrib>Robinson, Jennifer L., MS</creatorcontrib><creatorcontrib>Moss, Arthur J., MD</creatorcontrib><title>Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Long QT syndrome (LQTS) is one of several primary electrical disorders or hereditary arrhythmia syndromes along with the short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Since its initial recognition in 1957 by Jervell and Lange-Nielsen ( Am Heart J. 1957;54:59-68), LQTS has been intimately associated with risk for sudden cardiac death. The implantable defibrillator was developed by Morowski et al ( N Engl J Med. 1980;303:322-4) as a treatment to prevent sudden cardiac death. Consequently, implanted cardioverter-defibrillator therapy deserves serious consideration as an important therapy for LQTS.</description><subject>Cardiac arrhythmia</subject><subject>Cardiovascular</subject><subject>Defibrillators, Implantable - adverse effects</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Long QT Syndrome - drug therapy</subject><subject>Long QT Syndrome - therapy</subject><subject>Mortality</subject><subject>Mutation</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kV-L1DAUxYMo7uzoB_BFAoJvrTdtmrYIgiy6CguiruBbyJ9bJ7VtapJZmW9vhhlY2AdfcnPhnMO9v0vICwYlAybejKXajWUF0JbASqiaR2TDoG8L0XL-mGwAoCq6FuoLchnjmFtRdeIpuWBt3fMe6g35-c1PSP1A3bxOaklK59aoYJ2_w5AwUIuD08FNk0o-0LTDoNYDdQtdVXK4pEj_urSjk19-0a-3NB4WG_yMz8iTQU0Rn5_rlvz4-OH26lNx8-X689X7m8LUvE9FY3VfM20EaitUJ8BoZgbQtjc617pVHbQ9tqxnjDUV543umK5qITprNeP1lrw-5a7B_9ljTHJ20WAed0G_jzJvXzV9frfk1QPh6PdhybNJ1gAXHDqosoqdVCb4GAMOcg1uVuEgGcgjdDnKDF0eoUtgMkPPnpfn5L2e0d47zpSz4O1JgBnEncMgo8noDFoX0CRpvftv_LsHbjO5xRk1_cYDxvstZKwkyO_Hqx-PDm3-dZzV_wAxQ6bC</recordid><startdate>200704</startdate><enddate>200704</enddate><creator>Daubert, James P., MD</creator><creator>Zareba, Wojciech, MD, PhD</creator><creator>Rosero, Spencer Z., MD</creator><creator>Budzikowski, Adam, MD, PhD</creator><creator>Robinson, Jennifer L., MS</creator><creator>Moss, Arthur J., MD</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200704</creationdate><title>Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome</title><author>Daubert, James P., MD ; Zareba, Wojciech, MD, PhD ; Rosero, Spencer Z., MD ; Budzikowski, Adam, MD, PhD ; Robinson, Jennifer L., MS ; Moss, Arthur J., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-5db931bc6ebd6a860cb1cf0bd9cbcf037a8079e71911152445b81b23668ddb143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Cardiac arrhythmia</topic><topic>Cardiovascular</topic><topic>Defibrillators, Implantable - adverse effects</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Long QT Syndrome - drug therapy</topic><topic>Long QT Syndrome - therapy</topic><topic>Mortality</topic><topic>Mutation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daubert, James P., MD</creatorcontrib><creatorcontrib>Zareba, Wojciech, MD, PhD</creatorcontrib><creatorcontrib>Rosero, Spencer Z., MD</creatorcontrib><creatorcontrib>Budzikowski, Adam, MD, PhD</creatorcontrib><creatorcontrib>Robinson, Jennifer L., MS</creatorcontrib><creatorcontrib>Moss, Arthur J., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daubert, James P., MD</au><au>Zareba, Wojciech, MD, PhD</au><au>Rosero, Spencer Z., MD</au><au>Budzikowski, Adam, MD, PhD</au><au>Robinson, Jennifer L., MS</au><au>Moss, Arthur J., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2007-04</date><risdate>2007</risdate><volume>153</volume><issue>4</issue><spage>53</spage><epage>58</epage><pages>53-58</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Long QT syndrome (LQTS) is one of several primary electrical disorders or hereditary arrhythmia syndromes along with the short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Since its initial recognition in 1957 by Jervell and Lange-Nielsen ( Am Heart J. 1957;54:59-68), LQTS has been intimately associated with risk for sudden cardiac death. The implantable defibrillator was developed by Morowski et al ( N Engl J Med. 1980;303:322-4) as a treatment to prevent sudden cardiac death. Consequently, implanted cardioverter-defibrillator therapy deserves serious consideration as an important therapy for LQTS.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>17394903</pmid><doi>10.1016/j.ahj.2007.01.025</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2007-04, Vol.153 (4), p.53-58 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70325970 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Cardiac arrhythmia Cardiovascular Defibrillators, Implantable - adverse effects Heart attacks Humans Long QT Syndrome - drug therapy Long QT Syndrome - therapy Mortality Mutation |
| title | Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A51%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20implantable%20cardioverter%20defibrillator%20therapy%20in%20patients%20with%20long%20QT%20syndrome&rft.jtitle=The%20American%20heart%20journal&rft.au=Daubert,%20James%20P.,%20MD&rft.date=2007-04&rft.volume=153&rft.issue=4&rft.spage=53&rft.epage=58&rft.pages=53-58&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2007.01.025&rft_dat=%3Cproquest_cross%3E70325970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504640802&rft_id=info:pmid/17394903&rft_els_id=1_s2_0_S0002870307000841&rfr_iscdi=true |